A Randomized, Double-Blind, Positive-Controlled Phase III Clinical Trial of an Anti-Rabies Monoclonal Antibody for Category III Rabies Exposure in Individuals Under 18 Years — China, 2021–2023

What is already known about this topic? Anti-rabies monoclonal antibodies in combination with rabies vaccines have demonstrated safety and immunogenicity as alternatives to rabies immunoglobulins for category III post-exposure prophylaxis in adults. What is added by this report? This randomized, double-blind, active-control phase III trial demonstrates the immunogenicity and safety of an anti-rabies monoclonal antibodies in individuals aged <18 years with category III rabies exposure. What are the implications for public health practice? These findings support the use of recombinant human monoclonal antibodies in pediatric populations and their potential role as alternative passive immunization options for category III rabies post-exposure prophylaxis in individuals aged <18 years.